We hypothesized that administering CD25-biased IL-2cx or ICs in an immunologically favorable context, such as following immune checkpoint blockade to reinvigorate immunosuppressed effector T cells in the tumor microenvironment, could preferentially activate tumor-specific effector T cells. Here, IL2RA is linked to neoplasm.